Calculate exact syringe units for the KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) pre-mixed blend. The dose shown is from the combined vial — no separate math needed.
Adjust vial, water, and dose — answer updates live
All three take the same units for the same dose. A smaller barrel just spreads it over more space.
on a U-100 syringe for a 2mg dose
Assumes the pre-blended 80 mg vial, 5:1:1:1 GHK-Cu : BPC-157 : TB-500 : KPV.
Add 3 mL BAC water to your 80 mg vial. Draw to 7.5 units on a U-100 syringe for a 2mg dose. This vial will last 40 doses.
Copy link saves these numbers in the address. Anyone who opens it sees the same draw.
Never miss a dose — 2mg daily, draw 7.5 units on U-100 syringe.
Tracking needs a free account, about 20 seconds
The calculator stays free without one
Does stacking four preclinical peptides in one vial actually make sense? The KLOW Blend (also called the KLOW Protocol) puts GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg) together in a fixed 5:1:1:1 ratio. It evolved from the three-peptide GLOW stack. The addition of KPV brought anti-inflammatory gut protection into the mix. Each component works through a separate mechanism. GHK-Cu is a copper-binding tripeptide first isolated by Loren Pickart in 1973. His gene expression studies (PMID 29986520) confirmed it modulates over 4,000 genes involved in collagen, elastin, and antioxidant enzyme production. BPC-157 is a 15-amino-acid gastric juice fragment. Predrag Sikiric's group in Zagreb has published over 100 preclinical papers showing it accelerates tendon outgrowth through FAK-paxillin signaling and protects gut mucosa (PMID 17713731). TB-500, a synthetic fragment of thymosin beta-4, promotes actin polymerization and cell migration. Goldstein's original work showed it increased keratinocyte migration 2- to 3-fold at concentrations as low as 10pg (PMID 10469335). KPV enters intestinal epithelial cells via the PepT1 transporter and suppresses NF-kB inflammatory signaling at nanomolar concentrations (Dalmasso et al., PMID 18061177). The typical community protocol runs 2000mcg total blend per day for 10 weeks, followed by 4 weeks off. Most of the interest comes from the GLP-1 companion use case. Users on semaglutide or tirzepatide report that KLOW reduces nausea and supports skin tightening during rapid weight loss. That framing is entirely anecdotal. No clinical endpoint data supports it. The FDA classified BPC-157 and GHK-Cu as Category 2 bulk drug substances in 2023-2024, restricting compounding pharmacy access. Both BPC-157 and TB-500 are WADA-prohibited. Single vials run $65 to $380 across research vendors, with most landing near $100 to $135.
One page: what is in the vial, the dose each tier delivers per component, syringe units, cycling, and where every number comes from.
Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
